News Focus
News Focus
Followers 149
Posts 26290
Boards Moderated 0
Alias Born 04/08/2004

Re: MayoMobile post# 393799

Wednesday, 12/21/2022 11:51:02 AM

Wednesday, December 21, 2022 11:51:02 AM

Post# of 518941
MayoMobile

Jesse,

What are your thoughts regarding Dr. Timo Grimmer's comments regarding Anavex's Blarcamesine for the treatment of Alzheimer's disease on the Roche podcast. It is interesting that Roche is #5 on the top 5 pharmaceutical companies in the world.

Roche and Dr. Timo Grimmer, Investigator in the Anavex Blarcamesine Phase 2b/3 trial for the treatment of early stage Alzheimer's disease, newest member of the Anavix SAB (Scientific Advisory Board)

Notice that Roche is giving Dr. Grimmer an opportunity to tell his observations from the CTAD Congress.

Dr. Timo Grimmer über die Highlights des CTAD (Clinical Trials on Alzheimer's Disease) Kongresses.

https://www.portal.roche.de/aktuelles/roche-podcasts/nervennahrung/podcast-ctad-2022-neuro-news-aus-san-francisco-highlights.html

We know and Roche knows:

Dr. Grimmer. “There is such a significant unmet medical need around the globe caused by Alzheimer’s disease and patients in the Phase 2b/3 ANAVEX®2-73-AD-004 study performed better even after a year despite the progression of this devastating disease. It would be groundbreaking for patients and their loved ones if healthcare professionals are able to provide a therapeutic which can be taken orally and is generally safe, which the study indicates, ANAVEX®2-73 (blarcamesine) is a likely candidate.”

Good luck and GOD bless,
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News